|
1.
|
|
10 p, 496.7 KB |
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis
/
Facon, Thierry (Lille University Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, South Korea) ;
Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ;
Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Yağci, Münci (Gazi University, Ankara, Turkey) ;
Cavo, Michele (Bologna University School of Medicine, Italy) ;
Yong, Kwee (University College Hospital, London, UK) ;
Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ;
Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ;
Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ;
Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 -  10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029
|
|
|
2.
|
|
8 p, 1.0 MB |
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
/
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ;
Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K (Winship Cancer Institute. Emory University) ;
Martin, Thomas (University of California San Francisco) ;
Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud) ;
Benboubker, Lotfi (Hôpital Bretonneau) ;
Mateos, Maria-Victoria (University Hospital de Salamanca) ;
Popat, Rakesh (University College London Hospitals) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Sidana, Surbhi (Stanford University of Medicine) ;
Delforge, Michele (University of Leuven) ;
Pei, Lixia (Janssen Research & Development) ;
Trancucci, Danielle (Janssen Research & Development) ;
Olyslager, Yunsi (Janssen Research & Development) ;
Uhlar, Clarissa (Janssen Research & Development) ;
Stephenson, Tara (Janssen Research & Development) ;
Rampelbergh, Rian Van (Janssen Research & Development) ;
Banerjee, Arnob (Janssen Research & Development) ;
Kobos, Rachel (Janssen Research & Development) ;
Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818
|
|
|
3.
|
|
9 p, 603.3 KB |
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
/
Martin, Thomas G. (University of California San Francisco, USA) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ;
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ;
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
San-Miguel, Jesús F. (Clínica Universidad de Navarra) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K. (Emory University, Atlanta, GA) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ;
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Bahlis, Nizar (University of Calgary, Canada) ;
Popat, Rakesh (University College London) ;
Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ;
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ;
Pei, Lixia (Janssen Research & Development, Raritan, NJ) ;
Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ;
Fastenau, John (Janssen Research & Development, Raritan, NJ) ;
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ;
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
4.
|
|
9 p, 1.5 MB |
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study
/
Martin, Thomas (University of California at San Francisco, USA) ;
Dimopoulos, Meletios (University of Athens, Greece) ;
Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ;
Yong, Kwee (University College Hospital, London, UK) ;
Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ;
Facon, Thierry (Lille University Hospital, France) ;
Hajek, Roman (University of Ostrava, Czech Republic) ;
Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ;
Baker, Ross (Murdoch University, Perth, Australia) ;
Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ;
Min, Chang-Ki (The Catholic University of Korea) ;
Pour, Ludek (University Hospital Brno (República Txeca)) ;
Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ;
Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ;
Casca, France (Ividata Life Science, Levallois-Perret, France) ;
Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ;
Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - 10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)
|
|
|
5.
|
|
25 p, 927.1 KB |
Neuron numbers link innovativeness with both absolute and relative brain size
/
Sol, Daniel (Centre de Recerca Ecològica i d'Aplicacions Forestals) ;
Olkowicz, Seweryn (Charles University) ;
Sayol, Ferran (Centre de Recerca Ecològica i d'Aplicacions Forestals) ;
Kocourek, Martin (Charles University) ;
Zhang, Yicheng (Charles University) ;
Marhounová, Lucie (Charles University) ;
Osadnik, Christin (University of Duisburg-Essen) ;
Corssmit, Eva (Centre de Recerca Ecològica i d'Aplicacions Forestals) ;
Garcia-Porta, Joan (Universitat de Barcelona. Departament de Genètica, Microbiologia i Estadística) ;
Martin, Thomas E. (University of Montana) ;
Lefebvre Louis (McGill University) ;
Němec, Pavel (Charles University)
A longstanding issue in biology is whether the intelligence of animals can be predicted by absolute or relative brain size. However, progress has been hampered by an insufficient understanding of how neuron numbers shape internal brain organization and cognitive performance. [...]
2022 - 10.1038/s41559-022-01815-x
Nature ecology & evolution, Vol. 6 (July 2022) , p. 1381-1389
|
|
|
6.
|
|
9 p, 982.6 KB |
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis
/
Spicka, Ivan (Charles University and General Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Facon, Thierry (Lille University Hospital) ;
Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital) ;
Lim, Andrew (Austin and Repatriation Medical Center) ;
Mikala, Gabor (South Pest Central Hospital) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Yağci, Münci (Gazi University) ;
Cavo, Michele (Università di Bologna) ;
Risse, Marie-Laure (Sanofi (França)) ;
Asset, Gaëlle (Sanofi (França)) ;
Macé, Sandrine (Sanofi (França)) ;
Van de Velde, Helgi (Sanofi) ;
Yong, Kwee (University College Hospital) ;
Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
